Amanda Squiers
Adult Health · Las Vegas, NVNPI 1184860983
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 62.2% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $18,177 and has fallen 65.7% since, to $6,239 in 2025. Among adult health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $85.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$22K
- Boston Scientific$6K
- Sumitomo Pharma America, Inc.$1K
- Medtronic$1K
- Astellas Pharma US Inc$1K
- Teleflex LLC$825
- plus $3K from 30 others
Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$210
What the payments were for
- Consulting fees$13,29137%
- Speaking & faculty fees$1090%
- Travel & lodging$10,98330%
- Food & beverage$11,21031%
- Education$5341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 116 | $22,459 |
| Boston Scientific | 29 | $6,126 |
| Sumitomo Pharma America, Inc. | 58 | $1,174 |
| Medtronic | 19 | $1,163 |
| Astellas Pharma US Inc | 32 | $1,012 |
| Teleflex LLC | 18 | $825 |
| Dendreon Pharmaceuticals LLC | 14 | $417 |
| AbbVie(2 entities) | 19 | $379 |
| Abbott | 1 | $338 |
| Johnson & Johnson | 13 | $275 |
| Urogen Pharma, Inc. | 11 | $260 |
| Myovant Sciences Inc. | 11 | $227 |
| Urovant Sciences Inc | 10 | $173 |
| Amgen | 8 | $150 |
| Bayer | 7 | $115 |
| Pfizer | 5 | $98 |
| Coloplast | 5 | $89 |
| Myriad Genetic Laboratories, Inc. | 4 | $84 |
| Endo Pharmaceuticals Inc. | 5 | $84 |
| 180 Medical, Inc. | 5 | $75 |
| Telix Pharmaceuticals | 3 | $70 |
| Accord Healthcare, Inc. | 3 | $61 |
| Antares Pharma, Inc. | 4 | $61 |
| Verity Pharmaceuticals Inc. | 2 | $51 |
| Blue Earth Diagnostics | 2 | $47 |
| Rochester Medical Corporation | 3 | $45 |
| Merck | 2 | $45 |
| Endo USA, Inc. | 2 | $38 |
| Immunitybio, Inc. | 2 | $34 |
| Galderma Laboratories, L.p. | 2 | $31 |
| Procept Biorobotics Corporation | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Tolmar, Inc. | 1 | $22 |
| Hollister Incorporated | 1 | $18 |
| Mission Pharmacal Company | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$24,141
- Bulkamid$2,640
- Axonics r-SNM System$855
- INTERSTIM$612
- UroLift System$358
- XACT$338
- UroLift ATC System$112
How this compares
$36,126 in reported general payments places this provider in the 95th percentile of 90 adult health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 292 | $227,417 |
| GemtesaVibegron | 33 | $29,650 |
| Solifenacin Succinate | 289 | $12,985 |
| Estradiol | 153 | $10,754 |
| Tamsulosin Hcl | 337 | $4,567 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 173 | $3,063 |
| Methenamine Hippurate | 36 | $2,937 |
| Finasteride | 227 | $2,713 |
| Potassium Citrate ErPotassium Citrate | 24 | $1,335 |
| Silodosin | 13 | $943 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $920 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 41 | $574 |
| Dutasteride | 15 | $406 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $247 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,012 | $227,417292 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1,174 | $29,65033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 adult health providers in Nevada.
Other adult health in Las Vegas
- Marcia Castro-RosenbergLas Vegas$64K
- Jasmina FornbacherLas Vegas$14K
- Marcella PomeranzLas Vegas$14K
- Karisa SonLas Vegas$10K
- Jessica LuceroLas Vegas$6K
- Monica LynamLas Vegas$5K
- Thomas McNeilLas Vegas$5K
- Roger ConantLas Vegas$4K
- Ruth RamirezLas Vegas$4K
- Gener CruzLas Vegas$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.